TOP 1288

Drug Profile

TOP 1288

Alternative Names: TOP-1288

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TopiVert
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 28 Jun 2017 AbbVie completes a phase II trial in Ulcerative colitis in Hungary, Latvia, Lithuania, Poland, United Kingdom, Czech Republic, Bulgaria and Ukraine (Rectal) (NCT02888379)
  • 02 Jun 2017 Topivert Pharma completes a phase I trial in Ulcerative colitis (In volunteers) in United Kingdom (PO) (NCT03071081)
  • 08 Feb 2017 Phase-I clinical trials in Ulcerative colitis (In volunteers) in United Kingdom (PO) (NCT03071081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top